Efforts to identify an optimal combination regimen and patient population are being made in an ongoing trial evaluating farletuzumab in multiple combinations, in patients with low-CA125, platinum-sensitive ovarian cancer (ClinicalTrials.gov Identifier: NCT02289950). This evidence concerns the gene MUC16 and ovarian cancer.